GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLine Rx Ltd (NAS:BLRX) » Definitions » Forward PE Ratio

BioLine Rx (BioLine Rx) Forward PE Ratio : 0.00 (As of May. 16, 2024)


View and export this data going back to 2011. Start your Free Trial

What is BioLine Rx Forward PE Ratio?

BioLine Rx's Forward PE Ratio for today is 0.00.

BioLine Rx's PE Ratio without NRI for today is 0.00.

BioLine Rx's PE Ratio for today is 0.00.


BioLine Rx Forward PE Ratio Historical Data

The historical data trend for BioLine Rx's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLine Rx Forward PE Ratio Chart

BioLine Rx Annual Data
Trend
Forward PE Ratio

BioLine Rx Quarterly Data
Forward PE Ratio

Competitive Comparison of BioLine Rx's Forward PE Ratio

For the Biotechnology subindustry, BioLine Rx's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioLine Rx's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioLine Rx's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where BioLine Rx's Forward PE Ratio falls into.



BioLine Rx Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


BioLine Rx  (NAS:BLRX) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


BioLine Rx Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of BioLine Rx's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


BioLine Rx (BioLine Rx) Business Description

Traded in Other Exchanges
Address
2 HaMa’ayan Street, Modi’in, ISR, 7177871
BioLine Rx Ltd is a pre-commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

BioLine Rx (BioLine Rx) Headlines

From GuruFocus

BioLineRx to Report First Quarter 2023 Results on May 24, 2023

By PRNewswire PRNewswire 05-17-2023